Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammanorm 165 mg/mL: pump vs rapid push for primary immunodeficiency
DRKS00008784Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jul 2015
- Countries
- 4
01
Overview
A Phase 3 trial of ALYGLO in Immunogenetic disorder, sponsored by Octapharma. Started Jul 2015; status: completed.
02
Drugs
ALYGLO
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on DRKS00008784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00008784.